엔버릭 바이오사이언시스(ENVB)는 NAS에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.62 (+1.25%), 시가총액 $4.27M, 52주 범위 $0.58 ~ $10.33.
Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuropsychiatric disorders; and Psybrary, a proprietary library. Enveric Biosciences, Inc. is headquartered in Cambridge, Massachusetts.
엔버릭 바이오사이언시스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 XTS에서 실시간으로 확인할 수 있습니다.
엔버릭 바이오사이언시스의 현재 주가는 $1.62 (+1.25%)입니다. XTS에서 실시간 시세와 차트를 확인할 수 있습니다.
엔버릭 바이오사이언시스의 시가총액은 약 $4.27M입니다.
Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in…